STUB1 and cardiovascular disorder: The interplay between CHIP and inflammation has been demonstrated to lead not only to the development of hematological malignancies, e.g., MPNs, myelodysplastic syndromes, de novo or secondary AML, but also to systemic effects and the onset of cardiometabolic disorders, e.g., HTN, T2DM, cardiovascular disease etc. [15,100,105].